MoonLake Immunotherapeutics announces that 12-week Phase 2 MIRA trial data for the Nanobody sonelokimab in hidradenitis suppurativa will be presented at the European Academy of Dermatology and Venereology Congress taking place from October 11-14 in Berlin, Germany. In June 2023, MoonLake announced positive topline 12-week Phase 2 MIRA trial results, achieving a landmark milestone as the first placebo-controlled randomized trial in HS to report positive top-line results using HiSCR75 as the primary endpoint. The 24-week Phase 2 MIRA trial data for Nanobody sonelokimab in hidradenitis suppurativa is anticipated imminently. In addition, top-line 12-week results for MoonLake’s Phase 2 ARGO trial with Nanobody sonelokimab in psoriatic arthritis are expected in the first half of November 2023, ahead of the American College of Rheumatology Conference, November 10-15.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on MLTX:
- Phase 2 MIRA primary analysis trial results (12-week) for MoonLake’s Nanobody® sonelokimab in hidradenitis suppurativa to be presented at a late-breaking session at the European Academy of Dermatology and Venereology Congress
- MoonLake Immunotherapeutics downgraded to Neutral from Buy at Bryan Garnier
- Scinai Immunotherapeutics announces results from preclinical NanoAbs study
- MoonLake faces less competition after Acelyrin failure, says Guggenheim
- MoonLake Immunotherapeutics price target raised to $59 from $41 at Barclays
Questions or Comments about the article? Write to editor@tipranks.com